Raymond James Financial upgraded shares of Catalent (NYSE:CTLT) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat.com reports. The brokerage currently has $48.00 price target on the stock. The analysts noted that the move was a valuation call.
A number of other analysts have also recently weighed in on CTLT. ValuEngine cut shares of Catalent from a buy rating to a hold rating in a report on Friday, December 1st. Royal Bank of Canada started coverage on shares of Catalent in a report on Wednesday, December 13th. They issued an outperform rating and a $46.00 price objective on the stock. Zacks Investment Research cut shares of Catalent from a hold rating to a sell rating in a report on Wednesday, December 20th. First Analysis started coverage on shares of Catalent in a report on Friday, January 5th. They issued an equal weight rating on the stock. Finally, Goldman Sachs started coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a buy rating and a $50.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Catalent has a consensus rating of Buy and an average price target of $45.64.
Shares of CTLT stock opened at $39.40 on Wednesday. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66. Catalent has a twelve month low of $27.48 and a twelve month high of $47.87. The firm has a market cap of $5,419.41, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 2.33 and a beta of 1.54.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business had revenue of $606.30 million for the quarter, compared to analysts’ expectations of $565.05 million. During the same quarter last year, the company earned $0.27 EPS. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. sell-side analysts anticipate that Catalent will post 1.53 EPS for the current fiscal year.
In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the transaction, the senior vice president now owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.70% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. boosted its position in shares of Catalent by 25.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock valued at $41,773,000 after purchasing an additional 210,296 shares in the last quarter. American International Group Inc. boosted its position in shares of Catalent by 2.6% during the 4th quarter. American International Group Inc. now owns 362,257 shares of the company’s stock valued at $14,882,000 after purchasing an additional 9,152 shares in the last quarter. Sei Investments Co. boosted its position in shares of Catalent by 119.1% during the 3rd quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock valued at $3,761,000 after purchasing an additional 51,212 shares in the last quarter. Eagle Boston Investment Management Inc. boosted its position in shares of Catalent by 40.0% during the 4th quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock valued at $306,000 after purchasing an additional 2,101 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Catalent by 25.1% during the 3rd quarter. Legal & General Group Plc now owns 133,466 shares of the company’s stock valued at $5,323,000 after purchasing an additional 26,756 shares in the last quarter. 99.89% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/24/raymond-james-financial-upgrades-catalent-ctlt-to-outperform.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.